IndustryCompany release

Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027

🇺🇸 Lifeloc Technologies, Inc (LCTC) · Mon 16 Nov 2026

The US breath alcohol specialist narrowed its quarterly loss and delayed the limited launch of its oral-fluid THC analyzer by three quarters, citing a shift in engineering focus and capital access.

Lifeloc Technologies reported net revenue of $2.522 million for the third quarter of 2026, the quarter ended 30 September, up 12% on the same period a year earlier. Gross margin was 43%, and the net loss narrowed to $85,000.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Lifeloc Technologies, Inc ↗

Article written by VigiEye from the official source (Lifeloc Technologies, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →